Skip to main content
Top
Published in: Current Treatment Options in Oncology 12/2023

13-12-2023 | Edema

Syndromes of Concurrent Hypertension, Diastolic Dysfunction, and Pulmonary or Peripheral Edema in Cardio-Oncology: Case Studies, Literature Review, and New Classification System

Authors: Rebekah Summey, MD, Rana Aliani, MD, Lindsey A. McAlarnen, MD MSc, Nicole Sequeira, MD, Tahseen Shaik, BS, Denise Uyar, MD, Sherry-Ann Brown, MD PhD

Published in: Current Treatment Options in Oncology | Issue 12/2023

Login to get access

Opinion statement

Individuals who have ever been diagnosed with cancer are at increased risk for cardiovascular conditions during and after cancer treatment. Especially during cancer treatment, cardiovascular conditions can manifest in many ways, including peripheral or pulmonary edema. Edema can indicate volume overload affecting the heart even without other unequivocal evidence of apparent diastolic or systolic left ventricular dysfunction, particularly at rest. We propose a novel algorithm to streamline the diagnostic evaluation and cardiovascular classification for cancer patients with edema. We initially advise prompt evaluation with a chest X-ray and echocardiogram. We then suggest classification into one of five categories based on the timing of presentation of edema relative to cancer treatment, as well as echocardiography results and the presence or absence of hypertension or lymphatic causes of edema. This classification tool can then be utilized to guide further cardiovascular management suggestions. These concurrent syndromes presenting as edema may indicate the development or aggravation of undiagnosed diastolic dysfunction with or without hypertension, even if transiently present only while on cancer treatment.
Literature
2.
go back to reference Herrmann J, Lenihan D, Armenian S, Barac A, Blaes A, Cardinale D, et al. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J. 2022;43:280–99.PubMedCrossRef Herrmann J, Lenihan D, Armenian S, Barac A, Blaes A, Cardinale D, et al. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J. 2022;43:280–99.PubMedCrossRef
3.
go back to reference de Boer RA, Aboumsallem JP, Bracun V, Leedy D, Cheng R, Patel S, et al. A new classification of cardio-oncology syndromes. Cardiooncology. 2021;7:24.PubMedPubMedCentral de Boer RA, Aboumsallem JP, Bracun V, Leedy D, Cheng R, Patel S, et al. A new classification of cardio-oncology syndromes. Cardiooncology. 2021;7:24.PubMedPubMedCentral
4.
go back to reference Kwan ML, Cheng RK, Iribarren C, Shen H, Laurent CA, Roh JM, et al. Risk of heart failure with preserved versus reduced ejection fraction in women with breast cancer. Breast Cancer Res Treat. 2022;193:669–75.PubMedPubMedCentralCrossRef Kwan ML, Cheng RK, Iribarren C, Shen H, Laurent CA, Roh JM, et al. Risk of heart failure with preserved versus reduced ejection fraction in women with breast cancer. Breast Cancer Res Treat. 2022;193:669–75.PubMedPubMedCentralCrossRef
5 .
go back to reference • Reding KW, Cheng RK, Vasbinder A, Ray RM, Barac A, Eaton CB, et al. Lifestyle and cardiovascular risk factors associated with heart failure subtypes in postmenopausal breast cancer survivors. JACC CardioOncol. 2022;4:53–65.PubMedPubMedCentralCrossRef • Reding KW, Cheng RK, Vasbinder A, Ray RM, Barac A, Eaton CB, et al. Lifestyle and cardiovascular risk factors associated with heart failure subtypes in postmenopausal breast cancer survivors. JACC CardioOncol. 2022;4:53–65.PubMedPubMedCentralCrossRef
6.
go back to reference Larsen CM, Garcia Arango M, Dasari H, Arciniegas Calle M, Adjei E, Rico Mesa J, et al. Association of anthracycline with heart failure in patients treated for breast cancer or lymphoma, 1985–2010. JAMA Netw Open. 2023;6:e2254669.PubMedPubMedCentralCrossRef Larsen CM, Garcia Arango M, Dasari H, Arciniegas Calle M, Adjei E, Rico Mesa J, et al. Association of anthracycline with heart failure in patients treated for breast cancer or lymphoma, 1985–2010. JAMA Netw Open. 2023;6:e2254669.PubMedPubMedCentralCrossRef
7.
go back to reference • Solomon SD, Rizkala AR, Lefkowitz MP, Shi VC, Gong J, Anavekar N, et al. Baseline characteristics of patients with heart failure and preserved ejection fraction in the PARAGON-HF Trial. Circ Heart Fail. 2018;11:e004962.PubMedCrossRef • Solomon SD, Rizkala AR, Lefkowitz MP, Shi VC, Gong J, Anavekar N, et al. Baseline characteristics of patients with heart failure and preserved ejection fraction in the PARAGON-HF Trial. Circ Heart Fail. 2018;11:e004962.PubMedCrossRef
8.
go back to reference Brown S-AN, Doolittle DA, Bohanon CJ, Jayaraj A, Naidu SG, Huettl EA, et al. Quadrilateral space syndrome: the Mayo Clinic experience with a new classification system and case series. Mayo Clin Proc. 2015;90:382–94. Brown S-AN, Doolittle DA, Bohanon CJ, Jayaraj A, Naidu SG, Huettl EA, et al. Quadrilateral space syndrome: the Mayo Clinic experience with a new classification system and case series. Mayo Clin Proc. 2015;90:382–94.
10.
go back to reference Bertero E, Canepa M, Maack C, Ameri P. Linking heart failure to cancer: background evidence and research perspectives. Circulation. 2018;138:735–42.PubMedCrossRef Bertero E, Canepa M, Maack C, Ameri P. Linking heart failure to cancer: background evidence and research perspectives. Circulation. 2018;138:735–42.PubMedCrossRef
11.
go back to reference Yeboah J, Bertoni A, Qureshi W, Aggarwal S, Lima JAC, Kawel-Boehm N, et al. Pedal edema as an indicator of early heart failure in the community: prevalence and associations with cardiac structure/function and natriuretic peptides (MESA [Multiethnic Study of Atherosclerosis]). Circ Heart Fail. 2016;9:e003415.PubMedPubMedCentralCrossRef Yeboah J, Bertoni A, Qureshi W, Aggarwal S, Lima JAC, Kawel-Boehm N, et al. Pedal edema as an indicator of early heart failure in the community: prevalence and associations with cardiac structure/function and natriuretic peptides (MESA [Multiethnic Study of Atherosclerosis]). Circ Heart Fail. 2016;9:e003415.PubMedPubMedCentralCrossRef
12.
go back to reference Borlaug BA. The pathophysiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2014;11:507–15.PubMedCrossRef Borlaug BA. The pathophysiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2014;11:507–15.PubMedCrossRef
13.
go back to reference Li M, Kroetz DL. Bevacizumab-induced hypertension: clinical presentation and molecular understanding. Pharmacol Ther. 2018;182:152–60.PubMedCrossRef Li M, Kroetz DL. Bevacizumab-induced hypertension: clinical presentation and molecular understanding. Pharmacol Ther. 2018;182:152–60.PubMedCrossRef
14.
go back to reference Klein R, Nadouri D, Osler E, Johnson C, Dent S, Dwivedi G. Diastolic dysfunction can precede systolic dysfunction on MUGA in cancer patients receiving trastuzumab-based therapy. Nucl Med Commun. 2019;40:22–9.PubMedCrossRef Klein R, Nadouri D, Osler E, Johnson C, Dent S, Dwivedi G. Diastolic dysfunction can precede systolic dysfunction on MUGA in cancer patients receiving trastuzumab-based therapy. Nucl Med Commun. 2019;40:22–9.PubMedCrossRef
15.
go back to reference Kataoka H. Clinical characteristics of lower-extremity edema in stage A cardiovascular disease status defined by the ACC/AHA 2001 Chronic Heart Failure Guidelines. Clin Cardiol. 2013;36:555–9.PubMedPubMedCentralCrossRef Kataoka H. Clinical characteristics of lower-extremity edema in stage A cardiovascular disease status defined by the ACC/AHA 2001 Chronic Heart Failure Guidelines. Clin Cardiol. 2013;36:555–9.PubMedPubMedCentralCrossRef
16.
go back to reference Azzoli CG, Miller VA, Ng KK, Krug LM, Hensley ML, O’Reilly EM, et al. Gemcitabine-induced peripheral edema: report on 15 cases and review of the literature. Am J Clin Oncol. 2003;26:247–51.PubMedCrossRef Azzoli CG, Miller VA, Ng KK, Krug LM, Hensley ML, O’Reilly EM, et al. Gemcitabine-induced peripheral edema: report on 15 cases and review of the literature. Am J Clin Oncol. 2003;26:247–51.PubMedCrossRef
17.
go back to reference Katsenos S, Nikolopoulou M. Gemcitabine-induced severe peripheral edema in a patient with lung cancer. J Pharm Pract. 2012;25:393–5.PubMedCrossRef Katsenos S, Nikolopoulou M. Gemcitabine-induced severe peripheral edema in a patient with lung cancer. J Pharm Pract. 2012;25:393–5.PubMedCrossRef
18.
go back to reference Yang Y, Liu Y-H, Sun X, Yu M-W, Yang L, Cheng P-Y, et al. Risk of peripheral edema in cancer patients treated with MEK inhibitors: a systematic review and meta-analysis of clinical trials. Curr Med Res Opin. 2017;33:1663–75.PubMedCrossRef Yang Y, Liu Y-H, Sun X, Yu M-W, Yang L, Cheng P-Y, et al. Risk of peripheral edema in cancer patients treated with MEK inhibitors: a systematic review and meta-analysis of clinical trials. Curr Med Res Opin. 2017;33:1663–75.PubMedCrossRef
19.
go back to reference Tm O, A M, Jw R, Kw R, S M, Jc P, et al. Impact of hormonal therapies for treatment of hormone-dependent cancers (breast and prostate) on the cardiovascular system: effects and modifications: a scientific statement from the American Heart Association. Circulation Genomic and precision medicine [Internet]. Circ Genom Precis Med; 2021;14. Available from: https://pubmed.ncbi.nlm.nih.gov/33896190/. Accessed 13 Nov 2022. Tm O, A M, Jw R, Kw R, S M, Jc P, et al. Impact of hormonal therapies for treatment of hormone-dependent cancers (breast and prostate) on the cardiovascular system: effects and modifications: a scientific statement from the American Heart Association. Circulation Genomic and precision medicine [Internet]. Circ Genom Precis Med; 2021;14. Available from: https://​pubmed.​ncbi.​nlm.​nih.​gov/​33896190/​. Accessed 13 Nov 2022.
20.
go back to reference Stoltzfus KC, Zhang Y, Sturgeon K, Sinoway LI, Trifiletti DM, Chinchilli VM, et al. Fatal heart disease among cancer patients. Nat Commun. 2020;11:2011.PubMedPubMedCentralCrossRef Stoltzfus KC, Zhang Y, Sturgeon K, Sinoway LI, Trifiletti DM, Chinchilli VM, et al. Fatal heart disease among cancer patients. Nat Commun. 2020;11:2011.PubMedPubMedCentralCrossRef
21.
go back to reference Goldvaser H, Barnes TA, Šeruga B, Cescon DW, Ocaña A, Ribnikar D, et al. Toxicity of extended adjuvant therapy with aromatase inhibitors in early breast cancer: a systematic review and meta-analysis. J Natl Cancer Inst. 2018;110. Goldvaser H, Barnes TA, Šeruga B, Cescon DW, Ocaña A, Ribnikar D, et al. Toxicity of extended adjuvant therapy with aromatase inhibitors in early breast cancer: a systematic review and meta-analysis. J Natl Cancer Inst. 2018;110.
22.
go back to reference Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e895-1032.PubMed Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e895-1032.PubMed
23.
go back to reference Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, Dokainish H, Edvardsen T, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016;29:277–314.PubMedCrossRef Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, Dokainish H, Edvardsen T, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016;29:277–314.PubMedCrossRef
24.
go back to reference Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2014;15:1063–93.PubMedPubMedCentralCrossRef Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2014;15:1063–93.PubMedPubMedCentralCrossRef
25.
go back to reference Brønstad A, Berg A, Reed RK. Effects of the taxanes paclitaxel and docetaxel on edema formation and interstitial fluid pressure. Am J Physiol Heart Circ Physiol. 2004;287:H963-968.PubMedCrossRef Brønstad A, Berg A, Reed RK. Effects of the taxanes paclitaxel and docetaxel on edema formation and interstitial fluid pressure. Am J Physiol Heart Circ Physiol. 2004;287:H963-968.PubMedCrossRef
26.
go back to reference Hudis CA, Seidman AD, Crown JP, Balmaceda C, Freilich R, Gilewski TA, et al. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol. 1996;14:58–65.PubMedCrossRef Hudis CA, Seidman AD, Crown JP, Balmaceda C, Freilich R, Gilewski TA, et al. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol. 1996;14:58–65.PubMedCrossRef
27.
go back to reference Trudeau ME, Eisenhauer EA, Higgins BP, Letendre F, Lofters WS, Norris BD, et al. Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol. 1996;14:422–8.PubMedCrossRef Trudeau ME, Eisenhauer EA, Higgins BP, Letendre F, Lofters WS, Norris BD, et al. Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol. 1996;14:422–8.PubMedCrossRef
28.
go back to reference Piccart MJ, Klijn J, Paridaens R, Nooij M, Mauriac L, Coleman R, et al. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. J Clin Oncol. 1997;15:3149–55.PubMedCrossRef Piccart MJ, Klijn J, Paridaens R, Nooij M, Mauriac L, Coleman R, et al. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. J Clin Oncol. 1997;15:3149–55.PubMedCrossRef
30.
go back to reference Largeau B, Cracowski J-L, Lengellé C, Sautenet B, Jonville-Béra A-P. Drug-induced peripheral oedema: an aetiology-based review. Br J Clin Pharmacol. 2021;87:3043–55.PubMedCrossRef Largeau B, Cracowski J-L, Lengellé C, Sautenet B, Jonville-Béra A-P. Drug-induced peripheral oedema: an aetiology-based review. Br J Clin Pharmacol. 2021;87:3043–55.PubMedCrossRef
33.
go back to reference Wolf MB, Baynes JW. The anti-cancer drug, doxorubicin, causes oxidant stress-induced endothelial dysfunction. Biochim Biophys Acta. 2006;1760:267–71.PubMedCrossRef Wolf MB, Baynes JW. The anti-cancer drug, doxorubicin, causes oxidant stress-induced endothelial dysfunction. Biochim Biophys Acta. 2006;1760:267–71.PubMedCrossRef
34.
go back to reference Rassy EE, Assi T, Rizkallah J, Kattan J. Diffuse edema suggestive of cytokine release syndrome in a metastatic lung carcinoma patient treated with pembrolizumab. Immunotherapy. 2017;9:309–11.PubMedCrossRef Rassy EE, Assi T, Rizkallah J, Kattan J. Diffuse edema suggestive of cytokine release syndrome in a metastatic lung carcinoma patient treated with pembrolizumab. Immunotherapy. 2017;9:309–11.PubMedCrossRef
35.
go back to reference Pedrinelli R, Dell’Omo G, Melillo E, Mariani M. Amlodipine, enalapril, and dependent leg edema in essential hypertension. Hypertension. 2000;35:621–5.PubMedCrossRef Pedrinelli R, Dell’Omo G, Melillo E, Mariani M. Amlodipine, enalapril, and dependent leg edema in essential hypertension. Hypertension. 2000;35:621–5.PubMedCrossRef
36.
go back to reference Lexicomp App [Internet]. [cited 2023 Feb 24]. Available from: uptodate.com. Lexicomp App [Internet]. [cited 2023 Feb 24]. Available from: uptodate.com.
37.
go back to reference Minegishi S, Kinguchi S, Horita N, Namkoong H, Briasoulis A, Ishigami T, et al. Immune checkpoint inhibitors do not increase short-term risk of hypertension in cancer patients: a systematic literature review and meta-analysis. Hypertension. 2022;79:2611–21.PubMedCrossRef Minegishi S, Kinguchi S, Horita N, Namkoong H, Briasoulis A, Ishigami T, et al. Immune checkpoint inhibitors do not increase short-term risk of hypertension in cancer patients: a systematic literature review and meta-analysis. Hypertension. 2022;79:2611–21.PubMedCrossRef
38.
go back to reference •• Cohen JB, Brown NJ, Brown S-A, Dent S, van Dorst DCH, Herrmann SM, et al. Cancer therapy-related hypertension: a scientific statement from the American Heart Association. Hypertension. 2023;80:e46-57.PubMedCrossRef •• Cohen JB, Brown NJ, Brown S-A, Dent S, van Dorst DCH, Herrmann SM, et al. Cancer therapy-related hypertension: a scientific statement from the American Heart Association. Hypertension. 2023;80:e46-57.PubMedCrossRef
39.
go back to reference van Dorst DCH, Dobbin SJH, Neves KB, Herrmann J, Herrmann SM, Versmissen J, et al. Hypertension and prohypertensive antineoplastic therapies in cancer patients. Circ Res. 2021;128:1040–61.PubMedPubMedCentralCrossRef van Dorst DCH, Dobbin SJH, Neves KB, Herrmann J, Herrmann SM, Versmissen J, et al. Hypertension and prohypertensive antineoplastic therapies in cancer patients. Circ Res. 2021;128:1040–61.PubMedPubMedCentralCrossRef
40.
go back to reference Solimando DA, Phillips ET, Weiss RB, Dawson NA, Diehl LF, Rickles NM. Hypertensive reactions associated with paclitaxel. Cancer Invest. 1996;14:340–2.PubMedCrossRef Solimando DA, Phillips ET, Weiss RB, Dawson NA, Diehl LF, Rickles NM. Hypertensive reactions associated with paclitaxel. Cancer Invest. 1996;14:340–2.PubMedCrossRef
41.
go back to reference Biglia N, Zanfagnin V, Daniele A, Robba E, Bounous VE. Lower body lymphedema in patients with gynecologic cancer. Anticancer Res. 2017;37:4005–15.PubMed Biglia N, Zanfagnin V, Daniele A, Robba E, Bounous VE. Lower body lymphedema in patients with gynecologic cancer. Anticancer Res. 2017;37:4005–15.PubMed
42.
go back to reference Hutchison NA. Diagnosis and treatment of edema and lymphedema in the cancer patient. Rehabil Nurs. 2018;43:229–42.PubMedCrossRef Hutchison NA. Diagnosis and treatment of edema and lymphedema in the cancer patient. Rehabil Nurs. 2018;43:229–42.PubMedCrossRef
43.
go back to reference Chung YJ, Choi KH, Lee SH, Shin D, Hong D, Park S, et al. Prognostic impact of indeterminate diastolic function in patients with functionally insignificant coronary stenosis. J Am Soc Echocardiogr. 2023;36:295-306.e5.PubMedCrossRef Chung YJ, Choi KH, Lee SH, Shin D, Hong D, Park S, et al. Prognostic impact of indeterminate diastolic function in patients with functionally insignificant coronary stenosis. J Am Soc Echocardiogr. 2023;36:295-306.e5.PubMedCrossRef
44.
45.
go back to reference Clark AL, Cleland JGF. Causes and treatment of oedema in patients with heart failure. Nat Rev Cardiol. 2013;10:156–70.PubMedCrossRef Clark AL, Cleland JGF. Causes and treatment of oedema in patients with heart failure. Nat Rev Cardiol. 2013;10:156–70.PubMedCrossRef
46.
go back to reference Redfield MM, Borlaug BA. Heart failure with preserved ejection fraction: a review. JAMA. 2023;329:827–38.PubMedCrossRef Redfield MM, Borlaug BA. Heart failure with preserved ejection fraction: a review. JAMA. 2023;329:827–38.PubMedCrossRef
47.
go back to reference Messerli FH, Rimoldi SF, Bangalore S. The transition from hypertension to heart failure: contemporary update. JACC Heart Fail. 2017;5:543–51.PubMedCrossRef Messerli FH, Rimoldi SF, Bangalore S. The transition from hypertension to heart failure: contemporary update. JACC Heart Fail. 2017;5:543–51.PubMedCrossRef
Metadata
Title
Syndromes of Concurrent Hypertension, Diastolic Dysfunction, and Pulmonary or Peripheral Edema in Cardio-Oncology: Case Studies, Literature Review, and New Classification System
Authors
Rebekah Summey, MD
Rana Aliani, MD
Lindsey A. McAlarnen, MD MSc
Nicole Sequeira, MD
Tahseen Shaik, BS
Denise Uyar, MD
Sherry-Ann Brown, MD PhD
Publication date
13-12-2023
Publisher
Springer US
Published in
Current Treatment Options in Oncology / Issue 12/2023
Print ISSN: 1527-2729
Electronic ISSN: 1534-6277
DOI
https://doi.org/10.1007/s11864-023-01141-9

Other articles of this Issue 12/2023

Current Treatment Options in Oncology 12/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine